Akso Health Group ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $13.8M-6.4% YoYTTM through 31 Mar 2026
Net Income -$18.7MTTM through 31 Mar 2026
Free Cash Flow -$12.8MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | -0.1% |
| EBITDA Margin | -132.5% |
| Operating Margin | -149.7% |
| Net Margin | -135.0% |
Returns
-80.3%ROE
-9.8%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio1.53x
Net Debt-$9.1Mnet cash position
Cash & Equivalents$170.6K
Quality Metrics
Altman Z-Score42.92
Piotroski F-Score6 / 9
FCF Margin-92.5%
Earnings-Beat Rate66.7%
Multi-Year Trend
RevenueFY2026: $13.8M
Diluted EPS-$0.01TTMFY2026: $-0.01
Dividend
No dividend
Capital Allocation
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Medical Devices and Social E-commerce | View detailsThe company is actively expanding into advanced healthcare technologies, including launching a proprietary Brain-Computer Interface (BCI) R&D program in April 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.